Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis:
Consensus Statements for the United Arab Emirates

Anwar   Al   Hammadi; Muna   Al   Murrawi; Huda    R.    Ali; Ashraf    M.    Reda; Hussein    A.    Dayem; Jawaher       Alnaqbi; Zaidoon       Abdelhadi; Samir       Hantirah; Ayman       Alnaeem; Fatima    Al.    Marzooqi; Amani       Alfalasi; Fatima       Albreiki; Khadija       Aljefri; Faiza   Al   Ali
doi:10.2174/02666211213145047
Abstract

Background: Psoriasis is a chronic, immune-mediated disease characterized by mild localized plaques to severe plaques involving any part of the skin; it has a pronounced effect on patients’ quality of life. In the United Arab Emirates (UAE), there are limited local guidelines for the management of patients with psoriasis in daily clinical practice.
Objectives: The study aimed to develop consensus statements for the evaluation and management of moderate-to-severe psoriasis in the UAE.
Methods: To develop consensus statements, the Emirates Dermatology Society set up advisory board meetings in which local key opinion leaders (KOLs), including dermatologists from the UAE, participated. A targeted literature review was conducted to review current international and regional guidelines on the management of psoriasis, based on which the statements were formulated. A final consensus on each statement was reached based on collective agreement among the KOLs.
Results: Consensus statements were generated with the intention of supporting physicians in clinical decision-making with respect to the classification of disease severity, treatment options including biologic and non-biologic systemic therapies, transitioning and adjusting of systemic therapies, and monitoring and management of psoriasis in special populations.
Conclusion: These consensus statements could provide useful, practical guidance on the diagnosis and management of patients with moderate-to-severe psoriasis and would cater to the needs of physicians in the UAE.
Keywords: Psoriasis, Consensus statement, Dermatology, Medication therapy management, Non-biologic therapy, Biologic therapy.
[1] 
National Psoriasis Foundation/USA. Statistics  Available from:
                    https://www.psoriasis.org/content/statistics.
[2] 
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol  2008; 58(5): 826-50.
[http://dx.doi.org/10.1016/j.jaad.2008.02.039] [PMID: 18423260] 
[3] 
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol  2019; 80(4): 1029-72.
[http://dx.doi.org/10.1016/j.jaad.2018.11.057] [PMID: 30772098] 
[4] 
Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol  2015; 29(12): 2277-94.
[http://dx.doi.org/10.1111/jdv.13354] [PMID: 26481193] 
[5] 
Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol  2017; 177(3): 628-36.
[http://dx.doi.org/10.1111/bjd.15665] [PMID: 28513835] 
[6] 
Nast A, Spuls PI, van der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol  2017; 31(12): 1951-63.
[http://dx.doi.org/10.1111/jdv.14454] [PMID: 28895202] 
[7] 
Strober BE, van der Walt JM, Armstrong AW, et al. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol Ther (Heidelb)  2019; 9(1): 5-18.
[http://dx.doi.org/10.1007/s13555-018-0279-5] [PMID: 30578464] 
[8] 
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol  2013; 149(10): 1180-5.
[http://dx.doi.org/10.1001/jamadermatol.2013.5264] [PMID: 23945732] 
[9] 
Nast A, Erdmann R, Hofelich V, et al. Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines. Arch Dermatol Res  2009; 301(8): 553-9.
[http://dx.doi.org/10.1007/s00403-009-0978-y] [PMID: 19609542] 
[10] 
Al Hammadi A, Al-Sheikh A, Ammoury A, et al. Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. J Dermatolog Treat  2017; 28(2): 129-35.
[http://dx.doi.org/10.1080/09546634.2016.1183763] [PMID: 27196814] 
[11] 
NICE. National Institute for Health and Care Excellence. Psoriasis: assessment and management. Clinical guideline [CG153] 2017. Available from:
                    https://www.nice.org.uk/guidance/cg153
[12] 
Hamadah IR, Al Raddadi AA, Bahamdan KA, et al. Saudi practical guidelines on biologic treatment of psoriasis. J Dermatolog Treat  2015; 26(3): 223-9.
[http://dx.doi.org/10.3109/09546634.2014.946882] [PMID: 25075955] 
[13] 
Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol  2000; 43(2 Pt 1): 281-5.
[http://dx.doi.org/10.1067/mjd.2000.106374] [PMID: 10906652] 
[14] 
Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol  2010; 130(4): 933-43.
[http://dx.doi.org/10.1038/jid.2009.391] [PMID: 20043014] 
[15] 
Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol  2010; 24(Suppl. 2): 10-6.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03562.x] [PMID: 20443995] 
[16] 
Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol  2006; 72(4): 315-21.
[http://dx.doi.org/10.4103/0378-6323.26722] [PMID: 16880586] 
[17] 
Mrowietz U, Kragballe K, Nast A, Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting. J Eur Acad Dermatol Venereol  2011; 25(Suppl. 3): 1-13.
[http://dx.doi.org/10.1111/j.1468-3083.2011.04033.x] [PMID: 21470314] 
[18] 
Paul C, Gourraud PA, Bronsard V, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol  2010; 24(Suppl. 2): 2-9.
[http://dx.doi.org/10.1111/j.1468-3083.2009.03561.x] [PMID: 20443994] 
[19] 
PSORIASIS TREATMENT: PHOTOTHERAPY: American Academy of Dermatology Association 2020. Available from:
                    https://www.aad.org/public/diseases/psoriasis/treatment/medications/phototherapy
[20] 
Lindqvist T, Salah LA, Gillstedt M, Wennberg AM, Osmancevic A. Methotrexate Management in Psoriasis: Are We Following the Guidelines? Acta Derm Venereol  2018; 98(4): 449-51.
[http://dx.doi.org/10.2340/00015555-2857] [PMID: 29199349] 
[21] 
Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol  2011; 165(5): 1109-17.
[http://dx.doi.org/10.1111/j.1365-2133.2011.10615.x] [PMID: 21910713] 
[22] 
Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med  2011; 365(17): 1586-96.
[http://dx.doi.org/10.1056/NEJMoa1010858] [PMID: 22029980] 
[23] 
Laharie D, Terrebonne E, Vergniol J, et al. [The liver and methotrexate]. Gastroenterol Clin Biol  2008; 32(2): 134-42. [The liver and methotrexate].
[http://dx.doi.org/10.1016/j.gcb.2007.11.002] [PMID: 18494155] 
[24] 
Berends MA, Snoek J, de Jong EM, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther  2006; 24(5): 805-11.
[http://dx.doi.org/10.1111/j.1365-2036.2006.03047.x] [PMID: 16918884] 
[25] 
Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol  2011; 25(Suppl. 2): 12-8.
[http://dx.doi.org/10.1111/j.1468-3083.2011.03991.x] [PMID: 21388454] 
[26] 
Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol  1996; 10(6): 369-75.
[http://dx.doi.org/10.1155/1996/213596] [PMID: 9193771] 
[27] 
Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol  2012; 67(3): 459-77.
[http://dx.doi.org/10.1016/j.jaad.2011.07.039] [PMID: 22018758] 
[28] 
Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol  2014; 70(3): 401.e1-401.e14.
[http://dx.doi.org/10.1016/j.jaad.2013.09.010] [PMID: 24528911] 
[29] 
Maza A, Montaudié H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol  2011; 25(Suppl. 2): 19-27.
[http://dx.doi.org/10.1111/j.1468-3083.2011.03992.x] [PMID: 21388455] 
[30] 
Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal  2013; 2013: 805705.
[http://dx.doi.org/10.1155/2013/805705] [PMID: 23983647] 
[31] 
Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol  2003; 120(2): 211-6.
[http://dx.doi.org/10.1046/j.1523-1747.2003.12040.x] [PMID: 12542524] 
[32] 
Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol  2015; 73(1): 37-49.
[http://dx.doi.org/10.1016/j.jaad.2015.03.049] [PMID: 26089047] 
[33] 
Bissonnette R, Haydey R, Rosoph LA, et al. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. J Eur Acad Dermatol Venereol  2018; 32(3): 403-10.
[http://dx.doi.org/10.1111/jdv.14647] [PMID: 29055155] 
[34] 
Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol  2016; 74(1): 134-42.
[http://dx.doi.org/10.1016/j.jaad.2015.09.001] [PMID: 26549249] 
[35] 
Methotrexate. Lake Forest, IL: Hospira, Inc 2011.
[36] 
Akhyani M, Chams-Davatchi C, Hemami MR, Fateh S. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. J Eur Acad Dermatol Venereol  2010; 24(12): 1447-51.
[http://dx.doi.org/10.1111/j.1468-3083.2010.03667.x] [PMID: 20384673] 
[37] 
Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med  2003; 349(7): 658-65.
[http://dx.doi.org/10.1056/NEJMoa021359] [PMID: 12917302] 
[38] 
Ranjan N, Sharma NL, Shanker V, Mahajan VK, Tegta GR. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J Dermatolog Treat  2007; 18(5): 295-300.
[http://dx.doi.org/10.1080/09546630701499291] [PMID: 17852635] 
[39] 
Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol  2001; 44(4): 643-51.
[http://dx.doi.org/10.1067/mjd.2001.112400] [PMID: 11260540] 
[40] 
Neoral® (cyclosporine). East Hanover, NJ: Novartis Pharmaceuticals Corporation 2009.
[41] 
Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat  2007; 18(5): 286-90.
[http://dx.doi.org/10.1080/09546630701418747] [PMID: 17852632] 
[42] 
Finzi A. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Dermatology  1993; 187(Suppl. 1): 8-18.
[http://dx.doi.org/10.1159/000247286] [PMID: 8369579] 
[43] 
Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol  1994; 130(3): 366-75.
[http://dx.doi.org/10.1111/j.1365-2133.1994.tb02935.x] [PMID: 8148280] 
[44] 
SORIATANE (acitretin). Research Triangle Park, NC: Stiefel Laboratories, Inc 2017.
[45] 
OTEZLA® (apremilast). Summit, NJ: Celgene Corporation 2019.
[46] 
Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol  2006; 54(3)(Suppl. 2): S101-11.
[http://dx.doi.org/10.1016/j.jaad.2005.11.1088] [PMID: 16488320] 
[47] 
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol  2008; 58(1): 106-15.
[http://dx.doi.org/10.1016/j.jaad.2007.09.010] [PMID: 17936411] 
[48] 
Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol  2012; 66(2): 241-51.
[http://dx.doi.org/10.1016/j.jaad.2010.12.005] [PMID: 21752491] 
[49] 
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol  2007; 56(1): 31.e1-31.e15.
[http://dx.doi.org/10.1016/j.jaad.2006.07.017] [PMID: 17097378] 
[50] 
Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol  2012; 167(1): 180-90.
[http://dx.doi.org/10.1111/j.1365-2133.2012.10941.x] [PMID: 22413944] 
[51] 
Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol  2012; 166(4): 861-72.
[http://dx.doi.org/10.1111/j.1365-2133.2012.10901.x] [PMID: 22356258] 
[52] 
Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol  2015; 172(1): 244-52.
[http://dx.doi.org/10.1111/bjd.13343] [PMID: 25132294] 
[53] 
Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the british association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol  2015; 135(11): 2632-40.
[http://dx.doi.org/10.1038/jid.2015.208] [PMID: 26053050] 
[54] 
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med  2014; 371(4): 326-38.
[http://dx.doi.org/10.1056/NEJMoa1314258] [PMID: 25007392] 
[55] 
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol  2015; 73(3): 400-9.
[http://dx.doi.org/10.1016/j.jaad.2015.05.013] [PMID: 26092291] 
[56] 
Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1year: Results from the CLEAR study. J Am Acad Dermatol  2017; 76(1): 60-69.e9.
[http://dx.doi.org/10.1016/j.jaad.2016.08.008] [PMID: 27663079] 
[57] 
Gordon KB, Colombel JF, Hardin DS. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med  2016; 375(21): 2102.
[http://dx.doi.org/10.1056/NEJMoa1512711] [PMID: 27959738] 
[58] 
Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol  2016; 175(2): 273-86.
[http://dx.doi.org/10.1111/bjd.14493] [PMID: 26914406] 
[59] 
Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med  2017; 376(16): 1551-60.
[http://dx.doi.org/10.1056/NEJMoa1607017] [PMID: 28423301] 
[60] 
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol  2017; 76(3): 405-17.
[http://dx.doi.org/10.1016/j.jaad.2016.11.041] [PMID: 28057360] 
[61] 
Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med  2015; 373(2): 136-44.
[http://dx.doi.org/10.1056/NEJMoa1501646] [PMID: 26154787] 
[62] 
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet  2019; 394(10201): 831-9.
[http://dx.doi.org/10.1016/S0140-6736(19)31773-8] [PMID: 31402114] 
[63] 
Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet  2017; 390(10091): 276-88.
[http://dx.doi.org/10.1016/S0140-6736(17)31279-5] [PMID: 28596043] 
[64] 
Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol  2015; 173(4): 930-9.
[http://dx.doi.org/10.1111/bjd.13932] [PMID: 26042589] 
[65] 
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol  2019; 33(3): 464-83.
[http://dx.doi.org/10.1111/jdv.15340] [PMID: 30793796] 
[66] 
Heffernan MP. Combining traditional systemic and biologic therapies for psoriasis. Semin Cutan Med Surg  2010; 29(1): 67-9.
[http://dx.doi.org/10.1016/j.sder.2010.03.003] [PMID: 20430311] 
[67] 
Navarro-Sarabia F, Ariza-Ariza R, Hernández-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. J Rheumatol  2006; 33(6): 1075-81.
[PMID: 16652437] 
[68] 
Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol  2012; 167(3): 649-57.
[http://dx.doi.org/10.1111/j.1365-2133.2012.11015.x] [PMID: 22533447] 
[69] 
Heinecke GM, Luber AJ, Levitt JO, Lebwohl MG. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J Drugs Dermatol  2013; 12(10): 1098-102.
[PMID: 24085044] 
[70] 
Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol  2014; 28(4): 438-53.
[http://dx.doi.org/10.1111/jdv.12118] [PMID: 23437792] 
[71] 
Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol  2014; 171(3): 485-91.
[http://dx.doi.org/10.1111/bjd.13060] [PMID: 24749725] 
[72] 
CIMZIA®(certolizumab pegol). Smyrna, GA: UCB, Inc 2019.
[73] 
Stelara® (ustekinumab). Horsham, PA: Janssen Pharmaceutical Companies 2019.
[74] 
CosentyxTM (secukinumab). East Hanover, NJ: Novartis Pharmaceuticals Corporation 2015.
[75] 
Siliq™ (brodalumab). Bridgewater, NJ: Valeant Pharmaceuticals North America LLC 2017.
[76] 
TALTZ® (ixekizumab). Indianapolis, IN: Eli Lilly and Company 2019.
[77] 
TREMFYATM (guselkumab). Horsham, PA: Janssen Biotech, Inc 2017.
[78] 
SKYRIZI™ (risankizumab-rzaa). North Chicago, IL: AbbVie Inc 2019.
[79] 
ILUMYA™ (tildrakizumab-asmn). Whitehouse Station, NJ: Merck & Co., Inc 2018.
[80] 
Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet  2001; 358(9287): 1042-5.
[http://dx.doi.org/10.1016/S0140-6736(01)06179-7] [PMID: 11589933] 
[81] 
Archier E, Devaux S, Castela E, et al. Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol  2012; 26(Suppl. 3): 11-21.
[http://dx.doi.org/10.1111/j.1468-3083.2012.04519.x] [PMID: 22512676] 
[82] 
Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol  2017; 77(5): 845-854.e5.
[http://dx.doi.org/10.1016/j.jaad.2017.07.013] [PMID: 28893407] 
[83] 
Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum  2013; 65(1): 48-58.
[http://dx.doi.org/10.1002/art.37740] [PMID: 23055441] 
[84] 
Patel S, Patel T, Kerdel FA. The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature. Int J Dermatol  2016; 55(5): 487-93.
[http://dx.doi.org/10.1111/ijd.13129] [PMID: 26711080] 
[85] 
Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies inpatients with immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology  2016; 151(1): 97-109.e4.
[http://dx.doi.org/10.1053/j.gastro.2016.03.037] [PMID: 27039969] 
[86] 
Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf  2016; 15(10): 1413-20.
[http://dx.doi.org/10.1080/14740338.2016.1221923] [PMID: 27545070] 
[87] 
Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis  2003; 3(3): 148-55.
[http://dx.doi.org/10.1016/S1473-3099(03)00545-0] [PMID: 12614731] 
[88] 
Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol  2008; 59(3): 363-80.
[http://dx.doi.org/10.1016/j.jaad.2008.05.033] [PMID: 18694676] 
[89] 
Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol  2012; 167(5): 1145-52.
[http://dx.doi.org/10.1111/j.1365-2133.2012.11142.x] [PMID: 22803615] 
[90] 
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol  2019; 33(9): 1676-84.
[http://dx.doi.org/10.1111/jdv.15653] [PMID: 31054215] 
[91] 
Centers for Disease Control and Prevention - Treatment for TB Disease 2016. Available from:
                    https://www.cdc.gov/tb/topic/treatment/tbdisease.htm
[92] 
Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep  2020; 69(1): 1-11.
[http://dx.doi.org/10.15585/mmwr.rr6901a1] [PMID: 32053584] 
[93] 
Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol  2014; 171(1): 17-29.
[http://dx.doi.org/10.1111/bjd.12941] [PMID: 24606161] 
[94] 
Barker J, Horn EJ, Lebwohl M, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol  2011; 25(7): 758-64.
[http://dx.doi.org/10.1111/j.1468-3083.2010.03932.x] [PMID: 21198946] 
[95] 
Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol  2016; 22(28): 6444-55.
[http://dx.doi.org/10.3748/wjg.v22.i28.6444] [PMID: 27605880] 
[96] 
Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. J Am Acad Dermatol  2017; 77(1): 88-97.e5.
[http://dx.doi.org/10.1016/j.jaad.2017.01.037] [PMID: 28495497] 
[97] 
Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol  2014; 33(2): 273-6.
[http://dx.doi.org/10.1007/s10067-013-2378-0] [PMID: 23975363] 
[98] 
Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol  2013; 19(44): 7867-73.
[http://dx.doi.org/10.3748/wjg.v19.i44.7867] [PMID: 24307780] 
[99] 
Dávila-Seijo P, Dauden E, Descalzo MA, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the BIOBADADERM registry. J Invest Dermatol  2017; 137(2): 313-21.
[http://dx.doi.org/10.1016/j.jid.2016.08.034] [PMID: 27677836] 
[100] 
HUMIRA® (adalimumab) 2018. Available from:
                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf
[101] 
Enbrel® (etanercept) 2020. Available from:
                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103795s5574s5577lbl.pdf
[102] 
Remicade® (infliximab). Horsham, PA: Janssen Biotech, Inc 2013.
[103] 
Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol  2015; 151(9): 961-9.
[http://dx.doi.org/10.1001/jamadermatol.2015.0718] [PMID: 25970800] 
[104] 
Carrascosa JM, Del-Alcazar E. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Rev Clin Immunol  2018; 14(4): 259-73.
[http://dx.doi.org/10.1080/1744666X.2018.1454835] [PMID: 29557200] 
[105] 
Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep  2004; 53(30): 683-6.
[PMID: 15295313] 
[106] 
Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol  2017; 3(1): 21-5.
[http://dx.doi.org/10.1016/j.ijwd.2016.12.003] [PMID: 28492050] 
[107] 
Puchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation : Aconsensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr  2019; 131(1-2): 29-44.
[http://dx.doi.org/10.1007/s00508-019-1448-y] [PMID: 30643992] 
[108] 
Prabhu SS, Suvarna P. Biological agents in pregnancy and lactation–A rational approach. J Skin Sexually Transmit Dis  2019; 1(2): 54-60.
[http://dx.doi.org/10.25259/JSSTD_19_2019] 
[109] 
National Psoriasis Foundation - Updated: COVID-19 Recommendations 2020. Available from:
                    https://www.psoriasis.org/advance/coronavirus
[110] 
International Psoriasis Council - IPC Statement on the Coronavirus (COVID-19) Outbreak 2020. Available from:
                    https://www.psoriasiscouncil.org/blog/Statement-on-COVID-19-and-Psoriasis.htm
[111] 
GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) - Guidance for Psoriasis and Psoriatic Arthritis Patients during COVID-19 pandemic 2020. Available from:
                    https://www.grappanetwork.org/covid-19-guidance-for-pso-and-psa-patients
[112] 
National Institute for Health and Care Excellence - COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NICE guideline [NG169]) 2020. Available from:
                    https://www.nice.org.uk/guidance/ng169/resources/covid19-rapid-guideline-dermatological-conditions-treated-with-drugs-affecting-the-immune-response-pdf-66141909147589
[113] 
British association of dermatologists - dermatology advice regarding medication acting on the immune system: Adults, paediatrics and young people 2020. Available from:
                    https://www.bad.org.uk
                        /shared/get-file.ashx?itemtype=document&id=6674